Consistent technological advancements, particularly in areas such as drug discovery and biotechnology, are driving growth in the pharma industry. However, challenges exist in the face of inflation and stricter regulations.
Hence, it could be ideal to buy solid pharma stocks Bristol-Myers Squibb Company (BMY) and Collegium Pharmaceutical, Inc. (COLL). However, it could be better to wait for a more opportune entry point in Pfizer Inc. (PFE) and avoid Vaxcyte, Inc. (PCVX).
